PMID- 32441892
OWN - NLM
STAT- MEDLINE
DCOM- 20210513
LR  - 20210513
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 9
IP  - 14
DP  - 2020 Jul
TI  - Effectiveness and safety of low-dose apatinib in advanced gastric cancer: A 
      real-world study.
PG  - 5008-5014
LID - 10.1002/cam4.3105 [doi]
AB  - Apatinib has been demonstrated to be effective and safe among patients with 
      gastric cancer failing after at least two lines chemotherapy. This study aimed to 
      evaluate its effectiveness and safety of low-dose apatinib for the treatment of 
      gastric cancer in real-world practice. We performed a prospective, multicenter 
      observation study in a real-world setting. Patients with advanced gastric cancer 
      more than 18 years old were eligible and received low-dose apatinib (500 mg or 
      250mg per day) therapy. The median progression-free survival (PFS), median 
      overall survival (OS), objective response rate (ORR), disease control rate (DCR), 
      and safety were assessed. Between September 2017 and April 2019, a total of 747 
      patients were enrolled. The mPFS was 5.56 months (95% CI 4.47-6.28), and mOS was 
      7.5 months (95% CI 6.74-8.88). Four patients achieved complete response, 47 
      achieved partial response, and 374 patients achieved stable disease. The ORR was 
      6.83% and DCR was 56.89%. In addition, multivariate Cox regression analysis 
      indicated that hand-foot syndrome was one independent predictor for PFS and OS. 
      The most common adverse events (AEs) at any grade were hypertension (36.55%), 
      proteinuria (10.26%), hand-foot syndrome (33.53%), fatigue (24.9%), anemia 
      (57.35%), leukopenia (44.49%), thrombocytopenia (34.21%), and neutropenia 
      (53.33%). Grade 3-4 AEs with incidences of 5% or greater were anemia (13.97%), 
      thrombocytopenia (7.14%), and neutropenia (6.67%). No treatment-related death was 
      observed during the treatment of apatinib. The prospective study suggested that 
      low-dose apatinib was an effective regimen for the treatment of advanced gastric 
      cancer with tolerable or controlled toxicity in real world. Trial registration: 
      NCT03333967.
CI  - (c) 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Du, Yingying
AU  - Du Y
AUID- ORCID: 0000-0002-5149-4632
AD  - Department of Oncology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
FAU - Cao, Qisheng
AU  - Cao Q
AD  - Department of Interventional Oncology, People's Hospital of Ma'anshan, Ma'anshan, 
      China.
FAU - Jiang, Congqiao
AU  - Jiang C
AD  - Department of Gastrointestinal Surgery, The First Affiliated Hospital of Bengbu 
      Medical College, Bengbu, China.
FAU - Liang, Hui
AU  - Liang H
AD  - Department of Tumor Radiotherapy, Lu'an Hospital of Traditional Chinese Medicine, 
      Lu'an, China.
FAU - Ning, Zhongliang
AU  - Ning Z
AD  - Department of Gastrointestinal Surgery, The First Affiliated Hospital of 
      University of Science and Technology of China (Anhui Provincial Cancer Hospital), 
      Hefei, China.
FAU - Ji, Chushu
AU  - Ji C
AD  - Department of Oncology, The First Affiliated Hospital of University of Science 
      and Technology of China, Hefei, China.
FAU - Wang, Jinguo
AU  - Wang J
AD  - Department of Gastrointestinal Surgery, Yijishan Hospital of WanNan Medical 
      College, Wuhu, China.
FAU - Zhou, Chaoping
AU  - Zhou C
AD  - Department of Surgical Oncology, Anqing Municipal Hospital, Anqing, China.
FAU - Jiang, Zonghui
AU  - Jiang Z
AD  - Department of Oncology, The First People's Hospital of Chuzhou City, Chuzhou, 
      China.
FAU - Yu, Changjun
AU  - Yu C
AD  - Department of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui 
      Medical University, Hefei, China.
FAU - Li, Lei
AU  - Li L
AD  - Department of Surgical Oncology, The First Affiliated Hospital of Bengbu Medical 
      College, Bengbu, China.
FAU - Zhao, Yong
AU  - Zhao Y
AD  - Department of Oncology, Lu'an Hospital of Traditional Chinese Medicine, Lu'an, 
      China.
FAU - Xu, Yuemei
AU  - Xu Y
AD  - Department of Oncology, Jinzhai Country Hospital of Traditional Chinese Medicine, 
      Lu'an, China.
FAU - Xu, Tengyun
AU  - Xu T
AD  - Department of Oncology, The First Affiliated Hospital of University of Science 
      and Technology of China, Hefei, China.
FAU - Hu, Wenjun
AU  - Hu W
AD  - Department of Oncology, People's Hospital of Fuyang City, Fuyang, China.
FAU - Wang, Daoqin
AU  - Wang D
AD  - Department of Gastrointestinal Surgery, Wanbei Coal-Electricity Group General 
      Hospital, Suzhou, China.
FAU - Cheng, Huaidong
AU  - Cheng H
AD  - Department of Oncology, The Second Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
FAU - Wang, Guihe
AU  - Wang G
AD  - Department of Gastrointestinal Surgery, People's Hospital of Tongling City, 
      Tongling, China.
FAU - Zhou, Jinhua
AU  - Zhou J
AD  - Department of Oncology, The First Affiliated Hospital of Anhui University of 
      Chinese Medicine, Hefei, China.
FAU - Wang, Song
AU  - Wang S
AD  - Department of Oncology, People's Hospital of Fuyang City, Fuyang, China.
FAU - Zhang, Yanshun
AU  - Zhang Y
AD  - Department of Oncology, Huainan First People's Hospital, Huainan, China.
FAU - Hu, Zhiqiang
AU  - Hu Z
AD  - Department of Oncology, Huaibei Miners General Hospital, Huaibei, China.
FAU - Li, Xinzhong
AU  - Li X
AD  - Department of Oncology, The People's Hospital of Huaibei, Huaibei, China.
FAU - Lu, Donghui
AU  - Lu D
AD  - Department of Oncology, The 901 Hospital of the Joint Logistic Support Force of 
      the People's Liberation Army of China, Hefei, China.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Department of Oncology, The Second People's Hospital of Wuhu, Wuhu, China.
FAU - Xie, Hua
AU  - Xie H
AD  - Department of Oncology, The People's Hospital of Xuancheng City, Xuancheng, 
      China.
FAU - Sun, Guoping
AU  - Sun G
AUID- ORCID: 0000-0002-4325-900X
AD  - Department of Oncology, The First Affiliated Hospital of Anhui Medical 
      University, Hefei, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03333967
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200522
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Progression-Free Survival
MH  - Prospective Studies
MH  - Pyridines/pharmacology/*therapeutic use
MH  - Stomach Neoplasms/*drug therapy/mortality
PMC - PMC7367613
OTO - NOTNLM
OT  - advanced gastric cancer
OT  - apatinib
OT  - real-world
COIS- All authors declare no potential conflict of interest.
EDAT- 2020/05/23 06:00
MHDA- 2021/05/14 06:00
PMCR- 2020/05/22
CRDT- 2020/05/23 06:00
PHST- 2020/02/03 00:00 [received]
PHST- 2020/03/23 00:00 [revised]
PHST- 2020/04/15 00:00 [accepted]
PHST- 2020/05/23 06:00 [pubmed]
PHST- 2021/05/14 06:00 [medline]
PHST- 2020/05/23 06:00 [entrez]
PHST- 2020/05/22 00:00 [pmc-release]
AID - CAM43105 [pii]
AID - 10.1002/cam4.3105 [doi]
PST - ppublish
SO  - Cancer Med. 2020 Jul;9(14):5008-5014. doi: 10.1002/cam4.3105. Epub 2020 May 22.